Get the latest Science News and Discoveries
New chelating agent reduces toxicity in PSMA radiopharmaceutical therapy - EurekAlert
A newly developed chelator can significantly reduce off-target toxicity in prostate-specific membrane antigen (PSMA) radiopharmaceutical therapy, according to research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting. By improving the bond between the radioactive metal ion and the PSMA-targeting antibody, the chelator can make PSMA therapy safer and more effective for patients.
None
Or read this on Eureka Alert